Castle Biosciences (CSTL) Free Cash Flow (2018 - 2026)

Castle Biosciences has reported Free Cash Flow for 9 years, with the latest figure at $6.6 million in Q2 2026.

• Quarterly Free Cash Flow fell 43.32% year-over-year to $6.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$489000.0 (down 101.42% YoY) and the FY2025 annual result came in at $28.3 million, down 22.48% from the prior year.
• Free Cash Flow rose to $6.6 million in Q2 2026 per CSTL's latest filing, from -$34.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $19.7 million in Q4 2025 and troughed at -$34.6 million in Q1 2026.
• A 5-year average of -$1.7 million and a median of -$2.4 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow sank 398.33% in 2022, then jumped 563.28% in 2024.
• Over 5 years, Free Cash Flow stood at -$7.8 million in 2022, then surged by 289.98% to $14.8 million in 2023, then grew by 13.55% to $16.8 million in 2024, then climbed by 17.56% to $19.7 million in 2025, then slumped by 66.83% to $6.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $6.6 million, -$34.6 million, and $19.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.